Physician profile
Eugene Go
NPI 1528052065
$1,678.96
in general payments reported to CMS, 2019-2025
19 companies · $31.35 in 2025
The $31.35 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $349 · 2021: $40.32 · 2022: $49.47 · 2023: $90.39 · 2024: $79.97 · 2025: $31.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $233.49 | 2019-2023 | |
| Novo Nordisk INC | $209.75 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $170.33 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $165.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $148.64 | 2019 | |
| Mannkind Corporation | $101.20 | 2019 | |
| Abbvie INC. | $92.50 | 2019-2020 | |
| Lilly USA, LLC | $91.78 | 2019-2023 | Lyumjev, Jardiance |
| Jazz Pharmaceuticals INC. | $76.50 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.29 | 2019-2020 | |
| Harmony Biosciences LLC | $48.66 | 2024-2025 | |
| Insulet Corporation | $46.69 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $43.82 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $38.10 | 2019-2020 | |
| Shire North American Group INC | $34.90 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.15 | 2020 | |
| Amneal Pharmaceuticals LLC | $28.76 | 2019 | |
| Xeris Pharmaceuticals, INC. | $26.94 | 2021-2023 | Gvoke Hypopen |
| Valeritas, INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.